Oxford Biomedica hosts a free webinar to showcase its AAV expertise
Oxford, UK – 27 August 2024: On Wednesday, September 11, 2024, Oxford Biomedica, a cell and gene therapy CDMO focused on quality and innovation, will host a free 60-minute webinar on its adeno-associated virus (AAV) development expertise and showcase its recent breakthroughs.
The webinar entitled “Enhancing AAV processing and efficacy by characterizing capsid and payload heterogeneity” You can expect presentations from:
-
Sarah Laughlin-Toth, PhD, senior scientist, analytical development at Oxford Biomedica
-
Thomas Thiers, Downstream Scientist, Purification Sciences at Oxford Biomedica
-
Alex Meola, Associate Director, AAV Downstream Process Development at Oxford Biomedica
Speakers will discuss how advanced characterization of AAV capsids, including their ingredients and surface properties, provides important insights into factors that affect product quality and efficacy. They will examine the impact of capsid modifications such as VP1 deamidation, production conditions such as bioreactor time and AAV localization, and capsid heterogeneity on AAV products. This knowledge is critical to improving the development and manufacturing of AAV-based therapies and has potential implications for improving product efficacy and patient safety.
The webinar will take place on 16:00 BST / 11:00 EDT / 17:00 CET on Wednesday, September 11, 2024followed by a live question and answer session. To register for the webinar, please click here.
-End-
Inquiries:
Oxford Biomedica plc:
Sebastien Ribault, Chief Commercial Officer – T: +44 (0) 1865 509 737 / E: [email protected]
ICR Council:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary Jane Elliott / Angela Gray / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-focused cell and gene therapy contract development and manufacturing organization (CDMO) with a mission to enable its customers to deliver life-changing therapies to patients around the world.
As one of the original pioneers in cell and gene therapy, OXB has over 25 years of experience with viral vectors; they are the driving force behind most cell and gene therapies. OXB works with some of the world’s most innovative pharmaceutical and biotechnology companies, providing expertise in viral vector development and manufacturing for lentiviruses, adeno-associated viruses (AAV), adenoviruses and other viral vector types. Oxford Biomedica’s world-class capabilities span from early development to commercialization. These capabilities are supported by robust quality assurance systems, analytical methods and extensive regulatory expertise.
OXB offers a variety of unique technologies for the production of viral vectors, including a 4th generation lentiviral vector system (TetraVectaTM System), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
Oxford Biomedica, a FTSE4Good member, is headquartered in Oxford, UK. The company has bioprocessing and manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, USA. For more information, visit www.oxb.com, and follow us on LinkedIn and YouTube.
